New
TBS Reveal™ receives CE MDR certification for opportunistic bone-fragility assessment on X-ray
Content intended for healthcare professionals. By continuing, you confirm you are a HCP.
We understand bone health
Creating an era where healthy bones are the norm
Medimaps builds imaging software that helps clinicians understand bone health, from the microarchitecture that determines whether bone will break to the fractures hiding in X-rays.
Osteoporosis affects ~500 million people worldwide1
Most go undetected2
The clinical need
Osteoporosis is a silent disease — until a bone breaks
One in three women and one in five men over 50 will break a bone because of osteoporosis.3
Yet the disease stays silent: Most people have no symptoms until a fracture happens2, and the tools meant to catch it miss too many people.
BMD alone can't identify bone quality
Bone density can appear normal, even while the structure is weak
1 in 3
women over 50 will suffer a fragility fracture3
>
€57
bn
annual cost of fragility fractures to European health systems4
30
%
of high-risk patients present with normal or osteopenic BMD5
37
M
fragility fractures worldwide each year — roughly 70 a minute6
About Medimaps
A medtech AI company built on bone science
We help clinicians reveal more from routine imaging — every patient, every scan — for better care.
TBS: The standard
We are the creators of Trabecular Bone Score® (TBS®), the global standard in bone microarchitecture assessment, cited in 35+ international clinical guidelines8.
DXA and X-ray
DXA-based microarchitecture assessment and X-ray-based fracture detection — the two most common modalities in MSK imaging — addressed by complementary solutions.
Certified and trusted
Medimaps is ISO 13485:2016 certified and MDSAP certified, with software deployed across 90+ countries7, and TBS® is cited in 35+ guidelines.
Medimaps · 2026
Two leaders in bone imaging, now one company
In early 2026, Medimaps and Radiobotics merged, bringing together the world's leading bone-microarchitecture technology and one of Europe's most widely deployed AI fracture-detection tools.
+
80+
employees across three continents
3
offices: Geneva, Copenhagen, and Wilmington
2
clinical modalities: DXA and X-ray
90+
countries with clinical deployments7
Our solutions
Four solutions, two modalities
Each is a distinct, validated solution; all together extending bone-health assessment from DXA to X-ray.
TBS · DXA
CE · FDA
The global standard in fracture-risk assessment. Bone microarchitecture assessment from routine DXA scans.
radiobotics · X-ray
CE
One of Europe's most deployed AI fracture-detection tools. Decision support for paediatric and adult patients.
TBS · DXA
CE · FDA pending
Turn existing imaging into opportunity. AI software that surfaces bone-fragility risk opportunistically from routine X-rays.
TBS · DXA
In development
Surgical planning deserves bone quality, not just bone density. Pre- and post-surgical bone assessment for orthopaedic planning.
Built into your workflow
Available on the systems clinicians already use
TBS Osteo™ adds bone-microarchitecture to routine DXA; RBfracture™ and TBS Reveal™ run on X-rays clinicians already take. Each meets clinicians in the imaging they already perform: No new hardware, no workflow disruption.
TBS Osteo is available on:
RBfracture is available through:
TBS · Trabecular Bone Score
The global standard in bone microarchitecture assessment
TBS® is a patented, validated analytical index derived from routine DXA scans, revealing the internal structural quality of bone that BMD cannot measure. More than a decade of peer-reviewed research underpins its clinical use worldwide.
4.5M+
TBS® evaluations performed annually7
1,600+
peer-reviewed publications7
35+
clinical guidelines citing TBS®8
90+
countries with clinical deployments7
Clinically proven
TBS evidence keeps growing
2026 · eClinicalMedicine
Gatineau, G., De Gruttola, M, et al.
2026 · Archives of Osteoporosis
The Effects of Spaceflight Countermeasures on Trabecular Bone Score (TBS) of the Lumbar Spine
Anderson, K.D., Spector, E.R., et al.
2026 · Transplantation
Kratochvílová, S., Brunová, J., et al.
R&D & CRO
Built on science, from the start
Every product we build is grounded in over a decade of peer-reviewed evidence and rigorous scientific validation. That same rigor extends into our CRO services.
Our Clinical Affairs, Research & Innovation (CARI) team partners with the world's leading pharmaceutical companies to use TBS® as a sensitive endpoint in clinical trials. Since 2019, we've supported 12+ trials as a trusted CRO partner.7
R&D pipeline
Building along the bone-health continuum
Every programme builds on the same validated science, IP, and regulatory infrastructure, extending assessments from the DXA suite into X-rays, and from fracture risk toward broader, deeper tools for bone health.
Technology
Trabecular Bone Score®
The measure of bone quality · 1,600+ studies
Active
Bone microarchitecture · 90+ countries · CE · FDA
Active
AI fracture detection · 44+ countries · CE
Active
Opportunistic X-ray bone fragility · CE · FDA pending
In development
Site-specific bone assessment for surgery
The road ahead
Broader & deeper
Tools across the bone-health continuum
About medimaps
The team behind the standard
A team combining deep clinical science, medtech commercialisation, and AI engineering across Geneva, Copenhagen, and Wilmington. Backed by seasoned Swiss corporate investors and technology-focused venture funds.
Prof. Didier Hans, PhD, MBA
CEO, Co-Founder & Board Member
Mads Jarner Brevadt, MSc
Chief Product & Technology Officer
Gino Fiore, MBA
Chief Commercial Officer
Vincent Zwaans
Chief Financial Officer & Chief Operating Officer
Guided by a Board of Directors of seasoned investors and med-tech executives, chaired by Pierre Strübin.
the latest
Newsroom
Say hello, whether you're a clinician, a research partner, or an investor.
TBS Osteo™ is intended exclusively for healthcare professionals and is not available for purchase by the general public. TBS Osteo is a Class IIa medical device, CE marked under EU MDR 2017/745 (CE 2460). TBS Osteo is FDA 510(k) cleared (K243218) for use in the United States. TBS Osteo is included on the Australian Register of Therapeutic Goods (ARTG No. 528950) as "Inovanz Pty Ltd — X-ray system, diagnostic, general-purpose, application program software". Manufacturer: Medimaps Group SA, Chemin du Champ-des-Filles 36A, 1228 Plan-les-Ouates, Geneva, Switzerland. Always follow the instructions for use.
RBfracture™ is intended exclusively for healthcare professionals and is not available for purchase by the general public. RBfracture is a Class IIa medical device, CE marked under EU MDR 2017/745 (CE 0123). RBfracture is included on the Australian Register of Therapeutic Goods (ARTG No. 484605) as “Emergo Asia Pacific Pty Ltd T/a Emergo Australia - X-ray image interpretive software”. Manufacturer: Radiobotics ApS, Esplanaden 8C, 1tv, 1263, Copenhagen, Denmark. Always follow the instructions for use.
TBS Reveal™ is intended exclusively for healthcare professionals and is not available for purchase by the general public. TBS Reveal is a Class IIa medical device, CE marked under EU MDR 2017/745 (CE 2460). FDA clearance is pending; TBS Reveal is not available for clinical use in the United States. Manufacturer: Medimaps Group SA, Chemin du Champ-des-Filles 36A, 1228 Plan-les-Ouates, Geneva, Switzerland. Always follow the instructions for use.
TBS Ortho™ is currently under development and is not yet CE marked, FDA cleared, or otherwise registered for clinical use in any jurisdiction. It is not available for purchase or clinical use at this time.
References (8)
1. Kanis, J.A., McCloskey, E.V., Johansson, H., Oden, A., Melton, L.J. and Khaltaev, N. (2008). A reference standard for the description of osteoporosis. Bone, 42(3), pp.467–475. doi:10.1016/j.bone.2007.11.001.
2. Compston, J (2020). Reducing the treatment gap in osteoporosis. The Lancet Diabetes & Endocrinology, 8(1), pp.p7–9. doi:https://doi.org/10.1016/s2213-8587(19)30378-x.
3. International Osteoporosis Foundation (2024). Epidemiology of osteoporosis and fragility fractures | International Osteoporosis Foundation. [online] www.osteoporosis.foundation. Available at: https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures.
4. Kanis, J.A., Norton, N., Harvey, N.C., Jacobson, T., Johansson, H., Lorentzon, M., McCloskey, E.V., Willers, C. and Borgström, F. (2021). SCOPE 2021: A new scorecard for osteoporosis in Europe. Archives of Osteoporosis, 16(1). doi:10.1007/s11657-020-00871-9.
5. Hans, D., Goertzen, A.L., Krieg, M.-A. and Leslie, W. D (2011). Bone Microarchitecture Assessed by TBS Predicts Osteoporotic Fractures Independent of Bone Density: The Manitoba Study. Journal of Bone and Mineral Research, 26(11), pp.2762–2769. doi:10.1002/jbmr.499.
6. (2024). On World Osteoporosis Day, Experts Warn of Growing Burden of Fragility Fractures | International Osteoporosis Foundation. [online] Osteoporosis.foundation. Available at: https://www.osteoporosis.foundation/news/world-osteoporosis-day-experts-warn-growing-burden-fragility-fractures-20241018-0503.
7. Medimaps Group (2026) Internal data (data on file).
8. Enisa Shevroja, Jean-Yves Reginster, Lamy, O., Al-Daghri, N.M., Chandran, M., Anne-Laurence Demoux, Kohlmeier, L., Marie-Paule Lecart, Osvaldo Daniel Messina, Bruno Muzzi Camargos, Payer, J., Sansin Tuzun, Veronese, N., Cooper, C., McCloskey, E. and Harvey, N.C. (2023). Update on the Clinical Use of Trabecular Bone Score (TBS) in the Management of Osteoporosis: Results of an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) Under the Auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. Osteoporosis International, 34(9), pp.1501–1529. doi:10.1007/s00198-023-06817-4.